USD 2.17
(-0.46%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 132.95 Million USD | 6.89% |
2022 | 124.38 Million USD | 33.15% |
2021 | 93.41 Million USD | -8.19% |
2020 | 101.75 Million USD | 74.98% |
2019 | 58.15 Million USD | 27.29% |
2018 | 45.68 Million USD | -75.58% |
2017 | 187.09 Million USD | 47.18% |
2016 | 127.12 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 149.24 Million USD | 6.31% |
2024 Q1 | 140.38 Million USD | 5.59% |
2023 Q4 | 132.95 Million USD | 3.79% |
2023 Q1 | 123 Million USD | -1.11% |
2023 Q2 | 124.54 Million USD | 1.25% |
2023 FY | 132.95 Million USD | 6.89% |
2023 Q3 | 128.1 Million USD | 2.86% |
2022 Q3 | 123.52 Million USD | 1.75% |
2022 Q1 | 126.62 Million USD | 35.55% |
2022 Q2 | 121.4 Million USD | -4.13% |
2022 Q4 | 124.38 Million USD | 0.7% |
2022 FY | 124.38 Million USD | 33.15% |
2021 Q3 | 88.58 Million USD | 9.73% |
2021 Q4 | 93.41 Million USD | 5.46% |
2021 Q2 | 80.72 Million USD | -3.94% |
2021 Q1 | 84.03 Million USD | -17.41% |
2021 FY | 93.41 Million USD | -8.19% |
2020 FY | 101.75 Million USD | 74.98% |
2020 Q1 | 63.41 Million USD | 9.05% |
2020 Q2 | 69.87 Million USD | 10.19% |
2020 Q4 | 101.75 Million USD | 39.31% |
2020 Q3 | 73.04 Million USD | 4.53% |
2019 Q2 | 54.82 Million USD | 0.92% |
2019 Q3 | 55.59 Million USD | 1.41% |
2019 Q4 | 58.15 Million USD | 4.59% |
2019 FY | 58.15 Million USD | 27.29% |
2019 Q1 | 54.32 Million USD | 18.91% |
2018 Q2 | 33.24 Million USD | 0.0% |
2018 FY | 45.68 Million USD | -75.58% |
2018 Q4 | 45.68 Million USD | 5.28% |
2018 Q3 | 43.39 Million USD | 30.53% |
2018 Q1 | - USD | -100.0% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | 187.09 Million USD | 0.0% |
2017 FY | 187.09 Million USD | 47.18% |
2016 FY | 127.12 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Abbott Laboratories | 34.38 Billion USD | 99.613% |
Allurion Technologies Inc. | 142.19 Million USD | 6.504% |
Artivion, Inc. | 510.61 Million USD | 73.963% |
Avanos Medical, Inc. | 456.1 Million USD | 70.85% |
Butterfly Network, Inc. | 84.22 Million USD | -57.86% |
Butterfly Network, Inc. | 84.22 Million USD | -57.86% |
Bio-Rad Laboratories, Inc. | 3.55 Billion USD | 96.263% |
Boston Scientific Corporation | 15.6 Billion USD | 99.148% |
CONMED Corporation | 1.46 Billion USD | 90.93% |
Edwards Lifesciences Corporation | 2.64 Billion USD | 94.971% |
Paragon 28, Inc. | 162.95 Million USD | 18.414% |
Glaukos Corporation | 478.64 Million USD | 72.224% |
Globus Medical, Inc. | 1.08 Billion USD | 87.782% |
Inspire Medical Systems, Inc. | 104.29 Million USD | -27.473% |
Integer Holdings Corporation | 1.41 Billion USD | 90.592% |
Medtronic plc | 39.56 Billion USD | 99.664% |
Myomo, Inc. | 5.59 Million USD | -2277.429% |
Nevro Corp. | 330.31 Million USD | 59.75% |
Owlet, Inc. | 73.79 Million USD | -80.153% |
Penumbra, Inc. | 377.36 Million USD | 64.768% |
Vicarious Surgical Inc. | 21.89 Million USD | -507.221% |
Smith & Nephew plc | 4.77 Billion USD | 97.213% |
Sonendo, Inc. | 49.74 Million USD | -167.287% |
STERIS plc | 4.74 Billion USD | 97.2% |
Stryker Corporation | 21.31 Billion USD | 99.376% |
Zimmer Biomet Holdings, Inc. | 9 Billion USD | 98.524% |